Immune-Onc Therapeutics
Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies targeting myeloid cells for blood cancers, solid tumors, and autoimmune diseases.
Overview of Immune-Onc Therapeutics
Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company based in Palo Alto, California. The company is dedicated to developing novel therapies targeting myeloid cells for the treatment of blood cancers, solid tumors, and autoimmune and inflammatory diseases. Immune-Onc Therapeutics focuses on myeloid cell surface proteins, which are considered the next wave of therapeutic targets in immunology and oncology.
Innovative Antibody Development
Immune-Onc Therapeutics is building a robust portfolio of novel antibodies aimed at modulating or depleting specific subsets of myeloid cells involved in disease pathogenesis. Their key development includes IO-202, a first-in-class antagonist antibody for LILRB4, and IO-108, a fully human IgG4 monoclonal antibody targeting LILRB2 (ILT4). These antibodies are targeted at blood cancers and autoimmune diseases, demonstrating significant advancements in targeted therapy.
IO-202: A Leading Drug Candidate
IO-202 is Immune-Onc Therapeutics' leading drug candidate. It is a first-in-class antagonist antibody that exhibits high affinity binding to LILRB4. IO-202 has demonstrated targeted depletion of leukemia blasts expressing LILRB4, and key immune cells in autoimmune and inflammatory diseases. It has received Orphan Drug designation for AML and CMML, as well as Fast Track designation from the U.S. FDA for relapsed or refractory AML and CMML.
Strategic Collaborations
Immune-Onc Therapeutics has established strategic partnerships with notable biopharmaceutical companies including BeiGene and Regeneron. These collaborations support the global development of their product pipeline, including IO-108. Additionally, a Roche-led global, randomized Phase 1b/2 study is evaluating IO-108 in combination with atezolizumab and bevacizumab as a potential first-line therapy for hepatocellular carcinoma (HCC).
Funding and Support
The company has garnered significant financial backing, including investment from the LLS Therapy Acceleration Program (TAP) and grants from the National Cancer Institute (NCI) and California Institute of Regenerative Medicine (CIRM). These funds are instrumental in advancing Immune-Onc Therapeutics' innovative research and development initiatives aimed at tackling some of the most challenging medical conditions.